FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 322:941-949 April 5, 1990 Number 14 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Zidovudine (AZT) is a potent inhibitor of the replication of the human immunodeficiency virus (HIV), and it has been shown to improve survival in advanced HIV disease. We conducted a randomized, double-blind trial in adults with asymptomatic HIV infection who had CD4+ cell counts of fewer than 500 per cubic millimeter on entry into the study. The subjects (92 percent male) were randomly assigned to one of three treatment groups: placebo (428 subjects); zidovudine, 500 mg per day (453); or zidovudine, 1500 mg per day (457). After a mean follow-up of 55 weeks (range, 19 to 107), 33 of the subjects assigned to placebo had the acquired immunodeficiency syndrome (AIDS), as compared with 11 of those assigned to receive 500 mg of zidovudine (P = 0.002; relative risk, 2.8; 95 percent confidence interval, 1.4 to 5.6) and 14 of those assigned to receive 1500 mg of zidovudine (P = 0.05; relative risk, 1.9; 95 percent confidence interval, 1.0 to 3.5). In the three treatment groups, the rates of progression (per 100 person-years) to either AIDS or advanced AIDS-related complex were 7.6, 3.6, and 4.3, respectively. As compared with those assigned to placebo, the subjects in the zidovudine groups had significant increases in the number of CD4+ cells and significant declines in p24 antigen levels. In the 1500-mg zidovudine group, severe hematologic toxicity (anemia or neutropenia) was more frequent than in the other groups (P less than 0.0001). In the 500-mg zidovudine group, nausea was the only toxicity that was significantly more frequent (in 3.3 percent) than in the placebo group (P = 0.001). We conclude that zidovudine is safe and effective in persons with asymptomatic HIV infection and fewer than 500 CD4+ cells per cubic millimeter. Additional study will be required to determine whether such treatment will ultimately improve survival for persons infected with HIV.

Source Information

University of California, San Francisco.

This article has been cited by other articles:

• Flynn, P. M., Rodman, J., Lindsey, J. C., Robbins, B., Capparelli, E., Knapp, K. M., Rodriguez, J. F., McNamara, J., Serchuck, L., Heckman, B., Martinez, J., the PACTG P1012 Team, (2007). Intracellular Pharmacokinetics of Once versus Twice Daily Zidovudine and Lamivudine in Adolescents. Antimicrob. Agents Chemother. 51: 3516-3522 [Abstract] [Full Text]  
• Papparella, I., Ceolotto, G., Berto, L., Cavalli, M., Bova, S., Cargnelli, G., Ruga, E., Milanesi, O., Franco, L., Mazzoni, M., Petrelli, L., Nussdorfer, G. G., Semplicini, A. (2007). Vitamin C prevents zidovudine-induced NAD(P)H oxidase activation and hypertension in the rat. Cardiovasc Res 73: 432-438 [Abstract] [Full Text]  
• Heit, B., Jones, G., Knight, D., Antony, J. M., Gill, M. J., Brown, C., Power, C., Kubes, P. (2006). HIV and Other Lentiviral Infections Cause Defects in Neutrophil Chemotaxis, Recruitment, and Cell Structure: Immunorestorative Effects of Granulocyte-Macrophage Colony-Stimulating Factor. J. Immunol. 177: 6405-6414 [Abstract] [Full Text]  
• Feola, D. J., Garvy, B. A. (2006). Combination Exposure to Zidovudine plus Sulfamethoxazole-Trimethoprim Diminishes B-Lymphocyte Immune Responses to Pneumocystis murina Infection in Healthy Mice. CVI 13: 193-201 [Abstract] [Full Text]  
• Ioannidis, J. P. A. (2005). Contradicted and Initially Stronger Effects in Highly Cited Clinical Research. JAMA 294: 218-228 [Abstract] [Full Text]  
• Lewis, L D, Amin, S, Civin, C I, Lietman, P S (2004). Ex vivo zidovudine (AZT) treatment of CD34+ bone marrow progenitors causes decreased steady state mitochondrial DNA (mtDNA) and increased lactate production. Hum Exp Toxicol 23: 173-185 [Abstract]  
• Katz, M. H. (2003). Multivariable Analysis: A Primer for Readers of Medical Research. ANN INTERN MED 138: 644-650 [Abstract] [Full Text]  
• DePAOLA, L. G. (2003). Managing the care of patients infected with bloodborne diseases. Journal of the American Dental Association 134: 350-358 [Abstract] [Full Text]  
• Berger, P. B. (2002). The XIV International AIDS Conference: a call for action ... now. CMAJ 167: 483-484 [Full Text]  
• Jordan, R., Gold, L., Cummins, C., Hyde, C. (2002). Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ 324: 757-757 [Abstract] [Full Text]  
• Smith, N P, Pozniak, A L (2002). The changing face of HIV. Imaging 14: 1-7 [Abstract] [Full Text]  
• Sabin, C. A., Phillips, A. N. (2001). Treatment comparisons in HIV infection: the benefits and limitations of observational cohort studies. J Antimicrob Chemother 47: 371-375 [Full Text]  
• (2001). Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial. Arch. Dis. Child. 84: 230-236 [Abstract] [Full Text]  
• Stevenson, L. W., Kormos, R. L. (2001). Mechanical cardiac support 2000: current applications and future trial design: June 15-16, 2000 Bethesda, Maryland. J Am Coll Cardiol 37: 340-370 [Full Text]  
• Ellenberg, S. S., Temple, R. (2000). Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 2: Practical Issues and Specific Cases. ANN INTERN MED 133: 464-470 [Abstract] [Full Text]  
• Paredes, R., Mocroft, A., Kirk, O., Lazzarin, A., Barton, S. E., van Lunzen, J., Katzenstein, T. L., Antunes, F., Lundgren, J. D., Clotet, B., for the EuroSIDA Study Group, (2000). Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe: Results From the EuroSIDA Study. Arch Intern Med 160: 1123-1132 [Abstract] [Full Text]  
• Easterbrook, P. J., Goodall, R. L., Babiker, A. G., Yu, L. M., Smith, D., Cooper, D. A., Gazzard, B. G. (1999). Are HIV-infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy?. J Antimicrob Chemother 43: 379-388 [Abstract] [Full Text]  
• Barnard, J., Meng, X.-L. (1999). Applications of multiple imputation in medical studies: from AIDS to NHANES. Stat Methods Med Res 8: 17-36 [Abstract]  
• Culnane, M., Fowler, M., Lee, S. S., McSherry, G., Brady, M., O'Donnell, K., Mofenson, L., Gortmaker, S. L., Shapiro, D. E., Scott, G., Jimenez, E., Moore, E. C., Diaz, C., Flynn, P. M., Cunningham, B., Oleske, J., for the Pediatric AIDS Clinical Trials Group Proto, (1999). Lack of Long-term Effects of In Utero Exposure to Zidovudine Among Uninfected Children Born to HIV-Infected Women. JAMA 281: 151-157 [Abstract] [Full Text]  
• Detels, R., Munoz, A., McFarlane, G., Kingsley, L. A., Margolick, J. B., Giorgi, J., Schrager, L. K., Phair, J. P., for the Multicenter AIDS Cohort Study Investigator, (1998). Effectiveness of Potent Antiretroviral Therapy on Time to AIDS and Death in Men With Known HIV Infection Duration. JAMA 280: 1497-1503 [Abstract] [Full Text]  
• de Haard, H. J. W., Kazemier, B., Koolen, M. J. M., Nijholt, L. J., Meloen, R. H., van Gemen, B., Hoogenboom, H. R., Arends, J.-W. (1998). Selection of Recombinant, Library-Derived Antibody Fragments against p24 for Human Immunodeficiency Virus Type 1 Diagnostics. CVI 5: 636-644 [Abstract] [Full Text]  
• Kemp, S. D., Shi, C., Bloor, S., Harrigan, P. R., Mellors, J. W., Larder, B. A. (1998). A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and L-2',3'-Dideoxy-3'-Thiacytidine. J. Virol. 72: 5093-5098 [Abstract] [Full Text]  
• Paltiel, A. D., Freedberg, K. A. (1998). The Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients. Interfaces 28: 34-51 [Abstract]  
• Owens, D. K., Brandeau, M. L., Sox, C. H. (1998). Effect of Relapse to High-Risk Behavior on the Costs and Benefits of a Program to Screen Women for Human Immunodeficiency Virus. Interfaces 28: 52-74 [Abstract]  
• Mirochnick, M., Capparelli, E., Dankner, W., Sperling, R. S., van Dyke, R., Spector, S. A. (1998). Zidovudine Pharmacokinetics in Premature Infants Exposed to Human Immunodeficiency Virus. Antimicrob. Agents Chemother. 42: 808-812 [Abstract] [Full Text]  
• Adams, J. M., Shelton, M. J., Hewitt, R. G., Grasela, T. H., DeRemer, M., Morse, G. D. (1998). Relationship between Didanosine Exposure and Surrogate Marker Response in Human Immunodeficiency Virus-Infected Outpatients. Antimicrob. Agents Chemother. 42: 821-826 [Abstract] [Full Text]  
• Tedder, R. S., Kaye, S., Loveday, C., Weller, I. V. D., Jeffries, D., Norman, J., Weber, J., Bourelly, M., Foxall, R., Babiker, A., Darbyshire, J. H. (1998). Comparison of Culture- and Non-Culture-Based Methods for Quantification of Viral Load and Resistance to Antiretroviral Drugs in Patients Given Zidovudine Monotherapy. J. Clin. Microbiol. 36: 1056-1063 [Abstract] [Full Text]  
• Paltiel, A. D., Scharfstein, J. A., Seage, G. R., Losina, E., Goldie, S. J., Weinstein, M. C., Craven, D. E., Freedberg, K. A. (1998). A Monte Carlo Simulation of Advanced HIV Disease: Application to Prevention of CMV Infection. Med Decis Making 18: S93-S105 [Abstract]  
• Hogg, R. S., Heath, K. V., Yip, B., Craib, K. J. P., O'Shaughnessy, M. V., Schechter, M. T., Montaner, J. S. G. (1998). Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy. JAMA 279: 450-454 [Abstract] [Full Text]  
• Drusano, G. L., Stein, D. S. (1998). Mathematical Modeling of the Interrelationship of CD4 Lymphocyte Count and Viral Load Changes Induced by the Protease Inhibitor Indinavir. Antimicrob. Agents Chemother. 42: 358-361 [Abstract] [Full Text]  
• Ioannidis, J. P. A. (1998). Effect of the Statistical Significance of Results on the Time to Completion and Publication of Randomized Efficacy Trials. JAMA 279: 281-286 [Abstract] [Full Text]  
• Vlahov, D., Graham, N., Hoover, D., Flynn, C., Bartlett, J. G., Margolick, J. B., Lyles, C. M., Nelson, K. E., Smith, D., Holmberg, S., Farzadegan, H. (1998). Prognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug Users: Plasma Viral Load and CD4+ Cell Count. JAMA 279: 35-40 [Abstract] [Full Text]  
• Hammer, S. M., Katzenstein, D. A., Hughes, M. D., Gundacker, H., Schooley, R. T., Haubrich, R. H., Henry, W. K., Lederman, M. M., Phair, J. P., Niu, M., Hirsch, M. S., Merigan, T. C., The AIDS Clinical Trials Group Study 175 Study Tea, (1996). A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter. NEJM 335: 1081-1090 [Abstract] [Full Text]  
• Katzenstein, D. A., Hammer, S. M., Hughes, M. D., Gundacker, H., Jackson, J. B., Fiscus, S., Rasheed, S., Elbeik, T., Reichman, R., Japour, A., Merigan, T. C., Hirsch, M. S., The AIDS Clinical Trials Group Study 175 Virology, (1996). The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic Millimeter. NEJM 335: 1091-1098 [Abstract] [Full Text]  
• Phillips, A. N, Smith, G. D., Johnson, M. A (1996). For Debate: Will we ever know when to treat HIV infection?. BMJ 313: 608-610 [Full Text]  
• Kitahata, M. M., Koepsell, T. D., Deyo, R. A., Maxwell, C. L., Dodge, W. T., Wagner, E. H. (1996). Physicians' Experience with the Acquired Immunodeficiency Syndrome as a Factor in Patients' Survival. NEJM 334: 701-707 [Abstract] [Full Text]  
• Pinching, A. J (1996). Managing HIV disease after Delta. BMJ 312: 521-522 [Full Text]  
• O'Brien, W. A., Hartigan, P. M., Martin, D., Esinhart, J., Hill, A., Benoit, S., Rubin, M., Simberkoff, M. S., Hamilton, J. D. (1996). Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS. NEJM 334: 426-431 [Abstract] [Full Text]  
• Eron, J. J., Benoit, S. L., Jemsek, J., MacArthur, R. D., Santana, J., Quinn, J. B., Kuritzkes, D. R., Fallon, M. A., Rubin, M., The North American HIV Working Party, (1995). Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter. NEJM 333: 1662-1669 [Abstract] [Full Text]  
• Volberding, P. A., Lagakos, S. W., Grimes, J. M., Stein, D. S., Rooney, J., Meng, T.-C., Fischl, M. A., Collier, A. C., Phair, J. P., Hirsch, M. S., Hardy, W. D., Balfour, H. H., Reichman, R. C., The AIDS Clinical Trials Group, (1995). A Comparison of Immediate with Deferred Zidovudine Therapy for Asymptomatic HIV-Infected Adults with CD4 Cell Counts of 500 or More per Cubic Millimeter. NEJM 333: 401-407 [Abstract] [Full Text]  
• Kinloch-de Loes, S., Hirschel, B. J., Hoen, B., Cooper, D. A., Tindall, B., Carr, A., Saurat, J.-H., Clumeck, N., Lazzarin, A., Mathiesen, L., Raffi, F., Antunes, F., von Overbeck, J., Luthy, R., Glauser, M., Hawkins, D., Baumberger, C., Yerly, S., Perneger, T. V., Perrin, L. (1995). A Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus Infection. NEJM 333: 408-413 [Abstract] [Full Text]  
• Ho, D. D. (1995). Time to Hit HIV, Early and Hard. NEJM 333: 450-451 [Full Text]  
• Connor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M. J., VanDyke, R., Bey, M., Shearer, W., Jacobson, R. L., Jimenez, E., O'Neill, E., Bazin, B., Delfraissy, J.-F., Culnane, M., Coombs, R., Elkins, M., Moye, J., Stratton, P., Balsley, J., The Pediatric AIDS Clinical Trials Group Protocol, (1994). Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment. NEJM 331: 1173-1180 [Abstract] [Full Text]  
• Lenderking, W. R., Gelber, R. D., Cotton, D. J., Cole, B. F., Goldhirsch, A., Volberding, P. A., Testa, M. A., The AIDS Clinical Trials Group, (1994). Evaluation of the Quality of Life Associated with Zidovudine Treatment in Asymptomatic Human Immunodeficiency Virus Infection. NEJM 330: 738-743 [Abstract] [Full Text]  
• Moore, R. D., Stanton, D., Gopalan, R., Chaisson, R. E. (1994). Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban Community. NEJM 330: 763-768 [Abstract] [Full Text]  
• Saag, M. S. (1994). What to Do When Zidovudine Fails. NEJM 330: 706-707 [Full Text]  
• Smith, G D, Egger, M (1994). Who benefits from medical interventions?. BMJ 308: 72-4 [Full Text]  
• Saag, M. S., Emini, E. A., Laskin, O. L., Douglas, J., Lapidus, W. I., Schleif, W. A., Whitley, R. J., Hildebrand, C., Byrnes, V. W., Kappes, J. C., Anderson, K. W., Massari, F. E., Shaw, G. M., The 661 Working Group L-697, (1993). A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase. NEJM 329: 1065-1072 [Abstract] [Full Text]  
• Cooper, D. A., Gatell, J. M., Kroon, S., Clumeck, N., Millard, J., Goebel, F.-D, Bruun, J. N., Stingl, G., Melville, R. L., Gonzalez-Lahoz, J., Stevens, J. W., Fiddian, A. P., The European-Australian Collaborative Group, (1993). Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic Millimeter. NEJM 329: 297-303 [Abstract] [Full Text]  
• Bartlett, J. G. (1993). Zidovudine Now or Later?. NEJM 329: 351-352 [Full Text]  
• Hirsch, M. S., D'Aquila, R. T. (1993). Therapy for Human Immunodeficiency Virus Infection. NEJM 328: 1686-1695 [Full Text]  
• Johnston, M., Hoth, D. (1993). Present status and future prospects for HIV therapies. Science 260: 1286-1293 [Abstract]  
• Tarabey, R., Schneider, M. M.E., Hoepelman, A. I.M., Borleffs, J. C.C. (1993). Primary Prophylaxis against Pneumocystis carinii Pneumonia. NEJM 328: 1499-1499 [Full Text]  
• De Angelis, D., Day, N., Gore, S., Gilks, W., McGee, M. (1993). AIDS: the statistical basis for public health. Stat Methods Med Res 2: 75-91 [Abstract]  
• Pantaleo, G., Graziosi, C., Fauci, A. S. (1993). The Immunopathogenesis of Human Immunodeficiency Virus Infection. NEJM 328: 327-335 [Full Text]  
• Lo, B. (1992). Ethical Dilemmas in HIV Infection: What Have We Learned?. J Law Med Ethics 20: 92-103  
• Wong, R. J. (1992). The Pharmacological Treatment of Human Immunodeficiency Virus Infection. Journal of Pharmacy Practice 5: 121-130 [Abstract]  
• Brookmeyer, R (1991). Reconstruction and future trends of the AIDS epidemic in the United States. Science 253: 37-42 [Abstract]  
• Bloom, D., Glied, S (1991). Benefits and costs of HIV testing. Science 252: 1798-1804 [Abstract]  
• McPherson, M. L. (1991). Management of AIDS and infectious complications. Home Health Care Management Practice 3: 17-24 [Abstract]  
• Vlahov, D. (1990). HIV-1 Infection In The Correctional Setting. Criminal Justice Policy Review 4: 306-318 [Abstract]  
• Hammett, T. M., Dubler, N. N. (1990). Clinical and Epidemiologic Research on HIV Infection and AIDS Among Correctional Inmates: Regulations, Ethics, and Procedures. Eval Rev 14: 482-501 [Abstract]  
• Mitsuya, H, Yarchoan, R, Broder, S (1990). Molecular targets for AIDS therapy. Science 249: 1533-1544 [Abstract]  
• (1990). AZT FOR ASYMPTOMATIC HIV INFECTION. JWatch General 1990: 1-1 [Full Text]